Nutex Health (NUTX) Stock Forecast, Price Target & Predictions
NUTX Stock Forecast
Nutex Health stock forecast is as follows: an average price target of $45.00 (represents a 96.76% upside from NUTX’s last price of $22.87) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
NUTX Price Target
The average price target for Nutex Health (NUTX) is $45.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $45.00. This represents a potential 96.76% upside from NUTX's last price of $22.87.
NUTX Analyst Ratings
According to 2 Wall Street analysts, Nutex Health's rating consensus is 'Buy'. The analyst rating breakdown for NUTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nutex Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | Anthony Vendetti | Maxim Group | $45.00 | $24.90 | 80.72% | 96.76% |
The latest Nutex Health stock forecast, released on Sep 18, 2024 by Anthony Vendetti from Maxim Group, set a price target of $45.00, which represents a 80.72% increase from the stock price at the time of the forecast ($24.90), and a 96.76% increase from NUTX last price ($22.87).
Nutex Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $45.00 | $45.00 |
| Last Closing Price | $22.87 | $22.87 | $22.87 |
| Upside/Downside | -100.00% | 96.76% | 96.76% |
In the current month, the average price target of Nutex Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nutex Health's last price of $22.87. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | Maxim Group | - | Buy | Initialise |
| Aug 21, 2024 | Benchmark | Buy | Buy | Hold |
| May 15, 2024 | Benchmark | Buy | Buy | Hold |
| Dec 23, 2022 | Benchmark | - | Buy | Initialise |
Nutex Health's last stock rating was published by Maxim Group on Sep 18, 2024. The company Initialise its NUTX rating from "null" to "Buy".
Nutex Health Financial Forecast
Nutex Health Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $69.67M | $62.72B | $58.92M | $56.33M | $53.72M |
| Avg Forecast | $93.41M | $86.29M | $88.35M | $80.28M | $79.98M | $73.22M | $68.20M | $64.80M | $69.70M | $63.00M | $62.05M | $56.05M | $49.95M |
| High Forecast | $93.41M | $86.29M | $88.35M | $80.28M | $79.98M | $77.05M | $68.20M | $64.80M | $69.70M | $63.00M | $62.05M | $56.05M | $49.95M |
| Low Forecast | $93.41M | $86.29M | $88.35M | $80.28M | $79.98M | $69.40M | $68.20M | $64.80M | $69.70M | $63.00M | $62.05M | $56.05M | $49.95M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 995.60% | 0.95% | 1.00% | 1.08% |
Nutex Health's average Quarter revenue forecast for Mar 24 based on 1 analysts is $64.80M, with a low forecast of $64.80M, and a high forecast of $64.80M. NUTX's average Quarter revenue forecast represents a -6.99% decrease compared to the company's last Quarter revenue of $69.67M (Dec 23).
Nutex Health EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-25.70M | $2.96B | $3.93M | $-698.79K | $-5.99M |
| Avg Forecast | $30.57M | $28.24M | $28.91M | $26.27M | $26.17M | $23.96M | $22.32M | $21.21M | $22.81M | $20.62M | $20.31M | $18.34M | $16.35M |
| High Forecast | $30.57M | $28.24M | $28.91M | $26.27M | $26.17M | $25.22M | $22.32M | $21.21M | $22.81M | $20.62M | $20.31M | $18.34M | $16.35M |
| Low Forecast | $30.57M | $28.24M | $28.91M | $26.27M | $26.17M | $22.71M | $22.32M | $21.21M | $22.81M | $20.62M | $20.31M | $18.34M | $16.35M |
| Surprise % | - | - | - | - | - | - | - | - | -1.13% | 143.55% | 0.19% | -0.04% | -0.37% |
1 analysts predict NUTX's average Quarter EBITDA for Dec 23 to be $22.81M, with a high of $22.81M and a low of $22.81M. This is -99.23% lower than Nutex Health's previous annual EBITDA (Sep 23) of $2.96B.
Nutex Health Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-31.62M | $-5.54B | $-3.48M | $-6.92M | $-10.66M |
| Avg Forecast | $3.43M | $1.42M | $7.60M | $-1.30M | $-708.18K | $-1.79M | $-2.16M | $11.75M | $15.57M | $-5.59M | $-5.59M | $-16.77M | $-16.77M |
| High Forecast | $3.43M | $1.42M | $7.60M | $-1.30M | $-708.18K | $2.09M | $-2.16M | $11.75M | $15.57M | $-5.59M | $-5.59M | $-16.77M | $-16.77M |
| Low Forecast | $3.43M | $1.42M | $7.60M | $-1.30M | $-708.18K | $-5.67M | $-2.16M | $11.75M | $15.57M | $-5.59M | $-5.59M | $-16.77M | $-16.77M |
| Surprise % | - | - | - | - | - | - | - | - | -2.03% | 991.32% | 0.62% | 0.41% | 0.64% |
Nutex Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NUTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nutex Health SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $8.50M | $7.79B | $10.01M | $9.08M | $6.31M |
| Avg Forecast | $23.95M | $22.13M | $22.66M | $20.59M | $20.51M | $18.78M | $17.49M | $16.62M | $17.87M | $16.16M | $15.91M | $14.37M | $12.81M |
| High Forecast | $23.95M | $22.13M | $22.66M | $20.59M | $20.51M | $19.76M | $17.49M | $16.62M | $17.87M | $16.16M | $15.91M | $14.37M | $12.81M |
| Low Forecast | $23.95M | $22.13M | $22.66M | $20.59M | $20.51M | $17.80M | $17.49M | $16.62M | $17.87M | $16.16M | $15.91M | $14.37M | $12.81M |
| Surprise % | - | - | - | - | - | - | - | - | 0.48% | 482.47% | 0.63% | 0.63% | 0.49% |
Nutex Health's average Quarter SG&A projection for Mar 24 is $16.62M, based on 1 Wall Street analysts, with a range of $16.62M to $16.62M. The forecast indicates a 95.51% rise compared to NUTX last annual SG&A of $8.50M (Dec 23).
Nutex Health EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.05 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Avg Forecast | $0.46 | $0.19 | $1.02 | $-0.17 | $-0.10 | $-0.24 | $-0.29 | $1.58 | $2.09 | $-0.75 | $-0.75 | $-2.25 | $-2.25 |
| High Forecast | $0.46 | $0.19 | $1.02 | $-0.17 | $-0.10 | $0.28 | $-0.29 | $1.58 | $2.09 | $-0.75 | $-0.75 | $-2.25 | $-2.25 |
| Low Forecast | $0.46 | $0.19 | $1.02 | $-0.17 | $-0.10 | $-0.76 | $-0.29 | $1.58 | $2.09 | $-0.75 | $-0.75 | $-2.25 | $-2.25 |
| Surprise % | - | - | - | - | - | - | - | - | -0.02% | 0.01% | 0.01% | 0.00% | 0.01% |
According to undefined Wall Street analysts, Nutex Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NUTX previous annual EPS of $NaN (undefined).
Nutex Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UTRS | Minerva Surgical | $0.01 | $5.00 | 49900.00% | Buy |
| HLTH | Cue Health | $0.04 | $8.00 | 19900.00% | Hold |
| HCTI | Healthcare Triangle | $0.46 | $2.00 | 334.78% | Buy |
| BEAT | HeartBeam | $2.30 | $10.00 | 334.78% | Buy |
| NUTX | Nutex Health | $22.32 | $45.00 | 101.61% | Buy |
| PRVA | Privia Health Group | $17.72 | $33.82 | 90.86% | Buy |
| EVH | Evolent Health | $23.19 | $43.00 | 85.42% | Buy |
NUTX Forecast FAQ
Is Nutex Health a good buy?
Yes, according to 2 Wall Street analysts, Nutex Health (NUTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of NUTX's total ratings.
What is NUTX's price target?
Nutex Health (NUTX) average price target is $45 with a range of $45 to $45, implying a 96.76% from its last price of $22.87. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Nutex Health stock go up soon?
According to Wall Street analysts' prediction for NUTX stock, the company can go up by 96.76% (from the last price of $22.87 to the average price target of $45), up by 96.76% based on the highest stock price target, and up by 96.76% based on the lowest stock price target.
Can Nutex Health stock reach $30?
NUTX's average twelve months analyst stock price target of $45 supports the claim that Nutex Health can reach $30 in the near future.
What are Nutex Health's analysts' financial forecasts?
Nutex Health's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $286.2M (high $290.03M, low $282.38M), average EBITDA is $93.66M (high $94.91M, low $92.41M), average net income is $7.09M (high $10.97M, low $3.22M), average SG&A $73.4M (high $74.38M, low $72.42M), and average EPS is $0.951 (high $1.47, low $0.431). NUTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $348.33M (high $348.33M, low $348.33M), average EBITDA is $113.99M (high $113.99M, low $113.99M), average net income is $11.14M (high $11.14M, low $11.14M), average SG&A $89.33M (high $89.33M, low $89.33M), and average EPS is $1.49 (high $1.49, low $1.49).
Did the NUTX's actual financial results beat the analysts' financial forecasts?
Based on Nutex Health's last annual report (Dec 2023), the company's revenue was $247.65M, which missed the average analysts forecast of $250.8M by -1.26%. Apple's EBITDA was $-16.944M, missing the average prediction of $82.07M by -120.65%. The company's net income was $-45.787M, beating the average estimation of $-12.386M by 269.65%. Apple's SG&A was $33.23M, missing the average forecast of $64.32M by -48.33%. Lastly, the company's EPS was $-0.07, missing the average prediction of $-1.662 by -95.79%. In terms of the last quarterly report (Dec 2023), Nutex Health's revenue was $69.67M, missing the average analysts' forecast of $69.7M by -0.04%. The company's EBITDA was $-25.697M, missing the average prediction of $22.81M by -212.66%. Nutex Health's net income was $-31.618M, missing the average estimation of $15.57M by -303.09%. The company's SG&A was $8.5M, missing the average forecast of $17.87M by -52.45%. Lastly, the company's EPS was $-0.05, missing the average prediction of $2.09 by -102.39%